The authors successfully applied the technique to treat mouse models of diabetes, acute kidney disease, and muscular dystrophy as a proof‐of‐concept.[50] This tool can be considered for use for THBS2 activation in vivo for HCC patients and as a combination treatment along with the use of 5‐FU for anticancer stemness targeting in HCC. This evidence concerns the gene THBS2 and muscular dystrophy.